

Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study.

Lång K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S
Eur Radiol. 2015 May 1. [Epub ahead of print]

Objective

To assess the performance of one-view DBT (mediolateral oblique view) in a population-based screening program in the city of Malmö, Sweden.

Materials and Methods

In this study, 7500 women underwent 1-view DBT and 2-view digital mammography in a single session (Mammomat Inspiration, Siemens AG Erlangen, Germany) that were independently read and scored by six experienced readers. The reading included blinded double reading and scoring in two independent reading arms: Reading arm DBT and Reading arm DM. Cancer detection rate, recall-rate and positive predictive value are the primary outcomes of the study.

Results

Below are the key findings of the study:

- Cancer Detection Rate Increased by 43% (8.9/1000 screens for DBT and 6.3/1000 screens for DM)
- Recall Rate increased by 43% (3.8% for DBT and 2.6% for DM)
- PPV for recall was 24% for DBT and DM
- 1-view DBT found more invasive cancers (17/21 cancers)
- Rate of DCIS was similar in DBT and DM
- Dose for 1-view DBT is 70% of 2-view DM

Limitations of the Study

- The study used tomosynthesis data from the Oslo study, which may not be reflective of U.S. practice
- The study did not look at annual screening, which is the standard of care in the U.S.

Conclusion

The authors suggest that suggest that one-view DBT may be a feasible option as a standalone breast cancer screening modality.

Presented by Hologic Medical Education

hologic.com | info@hologic.com | +1.781.999.7300

MISC-03521 REV 001 © Hologic 2015. All rights reserved. Views and opinions expressed herein by third parties are theirs alone and do not necessarily reflect those of Hologic. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For information on specific products available for sale in a particular country, please contact your local Hologic representative or write to womenshealth@hologic.com.